Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 63693 | 2.61 |
09:34 ET | 600 | 2.56 |
09:41 ET | 300 | 2.54 |
09:45 ET | 7895 | 2.52 |
09:52 ET | 5900 | 2.4996 |
09:56 ET | 200 | 2.48 |
09:57 ET | 5218 | 2.52 |
09:59 ET | 500 | 2.52 |
10:01 ET | 100 | 2.52 |
10:08 ET | 130 | 2.51 |
10:15 ET | 998 | 2.48 |
10:28 ET | 200 | 2.495 |
10:32 ET | 1095 | 2.5 |
10:53 ET | 650 | 2.51 |
11:04 ET | 1536 | 2.51 |
11:11 ET | 3180 | 2.5 |
11:13 ET | 159 | 2.5099 |
11:24 ET | 100 | 2.495 |
11:26 ET | 100 | 2.495 |
11:27 ET | 100 | 2.495 |
11:33 ET | 3342 | 2.48 |
11:36 ET | 200 | 2.49 |
11:38 ET | 572 | 2.52 |
11:44 ET | 100 | 2.52 |
11:45 ET | 200 | 2.53 |
11:54 ET | 332 | 2.53 |
11:56 ET | 200 | 2.53 |
12:00 ET | 1120 | 2.52 |
12:07 ET | 342 | 2.52 |
12:09 ET | 240 | 2.5301 |
12:12 ET | 1544 | 2.53 |
12:14 ET | 224 | 2.51 |
12:23 ET | 100 | 2.52 |
12:30 ET | 200 | 2.5101 |
12:38 ET | 800 | 2.5 |
12:50 ET | 500 | 2.4901 |
01:14 ET | 600 | 2.51 |
01:15 ET | 500 | 2.52 |
01:17 ET | 600 | 2.52 |
01:19 ET | 500 | 2.54 |
01:21 ET | 600 | 2.54 |
01:24 ET | 500 | 2.54 |
01:26 ET | 1222 | 2.52 |
01:28 ET | 400 | 2.54 |
01:30 ET | 1300 | 2.565 |
01:32 ET | 1000 | 2.56 |
01:33 ET | 400 | 2.57 |
01:35 ET | 2534 | 2.54 |
01:37 ET | 400 | 2.56 |
01:39 ET | 600 | 2.59 |
01:42 ET | 400 | 2.59 |
01:44 ET | 400 | 2.62 |
01:46 ET | 683 | 2.59 |
01:48 ET | 2120 | 2.56 |
01:50 ET | 500 | 2.57 |
01:51 ET | 500 | 2.59 |
01:53 ET | 1440 | 2.57 |
01:55 ET | 200 | 2.58 |
01:57 ET | 400 | 2.59 |
02:00 ET | 855 | 2.58 |
02:02 ET | 1882 | 2.58 |
02:04 ET | 900 | 2.6 |
02:06 ET | 1557 | 2.6 |
02:08 ET | 900 | 2.6 |
02:09 ET | 961 | 2.59 |
02:11 ET | 1490 | 2.58 |
02:13 ET | 600 | 2.59 |
02:15 ET | 800 | 2.59 |
02:18 ET | 1100 | 2.57 |
02:20 ET | 300 | 2.6 |
02:22 ET | 1762 | 2.58 |
02:24 ET | 300 | 2.6 |
02:26 ET | 600 | 2.6 |
02:27 ET | 500 | 2.61 |
02:29 ET | 6088 | 2.61 |
02:31 ET | 1200 | 2.62 |
02:33 ET | 600 | 2.63 |
02:36 ET | 1200 | 2.62 |
02:38 ET | 438 | 2.64 |
02:40 ET | 292 | 2.64 |
02:42 ET | 600 | 2.65 |
02:44 ET | 500 | 2.68 |
02:45 ET | 500 | 2.7 |
02:47 ET | 800 | 2.675 |
02:49 ET | 800 | 2.68 |
02:51 ET | 1282 | 2.66 |
02:54 ET | 600 | 2.68 |
02:56 ET | 400 | 2.67 |
02:58 ET | 1230 | 2.66 |
03:00 ET | 3846 | 2.625 |
03:02 ET | 500 | 2.65 |
03:03 ET | 500 | 2.66 |
03:05 ET | 1833 | 2.63 |
03:07 ET | 500 | 2.64 |
03:09 ET | 1170 | 2.66 |
03:12 ET | 790 | 2.66 |
03:14 ET | 1197 | 2.64 |
03:16 ET | 700 | 2.65 |
03:18 ET | 600 | 2.65 |
03:20 ET | 767 | 2.65 |
03:21 ET | 600 | 2.67 |
03:23 ET | 484 | 2.67 |
03:25 ET | 543 | 2.68 |
03:27 ET | 2084 | 2.66 |
03:30 ET | 500 | 2.68 |
03:32 ET | 850 | 2.6923 |
03:34 ET | 1196 | 2.66 |
03:36 ET | 1000 | 2.67 |
03:38 ET | 500 | 2.69 |
03:39 ET | 600 | 2.69 |
03:41 ET | 500 | 2.69 |
03:43 ET | 1200 | 2.68 |
03:45 ET | 2209 | 2.66 |
03:48 ET | 700 | 2.68 |
03:50 ET | 547 | 2.68 |
03:52 ET | 1498 | 2.66 |
03:54 ET | 1182 | 2.66 |
03:56 ET | 2421 | 2.65 |
03:57 ET | 1303 | 2.64 |
03:59 ET | 57227 | 2.64 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 138.9M | -0.7x | --- |
Actuate Therapeutics Inc | 139.7M | -5.0x | --- |
Prelude Therapeutics Inc | 140.3M | -1.4x | --- |
Outlook Therapeutics Inc | 141.9M | -0.7x | --- |
aTyr Pharma Inc | 137.9M | -2.0x | --- |
Invivyd Inc | 143.3M | -0.7x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $138.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-3.77 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.